ClinicalTrials.gg
CompletedNCT06841640Updated Aug 1, 2025

Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD

A Phase 1/2 interventional study of AERO-001 and AERO-002 in COPD, sponsored by AeroRx Therapeutics Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by AeroRx Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom — 59 open to participants now, 75 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · United Kingdom.

Enrollment
368th of 465
24 · median 80
Started
2025
with 24 others
Phase 1/2
10 of 620
1 open now
Registered
584th of 620
by date

Among the 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom, this one is the 368th largest by enrollment of the 465 interventional ones that give a count, is one of 25 that started in 2025, is one of 10 in phase 1/2, and was the 584th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

59 of the 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 620 studies in Pulmonary Disease, Chronic Obstructive with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a phase 1/phase 2a, single dose, crossover study conducted in two parts.

Part 1: Phase 1, open-label, 4-period crossover study in 8 healthy subjects to determine the optimal dose of AERO-001 and AERO-002, the active components of AERO-007 combo bronchodilator, using the systemic pharmacokinetic (PK) profile.

Part 2: Phase 2a, randomized, double-blind, placebo-controlled, 3-period crossover study in 16 subjects with COPD to determine the safety, tolerability, PK, and bronchodilator profile of AERO-007 inhalation solution administered via oral inhalation using a general-purpose nebulizer.

Read the detailed description

According to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] guidelines, combination of a long-acting beta-agonist (LABA) bronchodilator and a long-acting muscarinic antagonist (LAMA) bronchodilator is the preferred choice for initial pharmacotherapy for COPD patients with high symptom severity, frequently experiencing breathlessness and patients with high exacerbation risk.

Although there are currently multiple LABA+LAMA combination bronchodilators available in an inhaler (MDI, DPI, and SMI), a significant number of COPD patients, generally high risk and older patients, do not receive optimal benefit from inhalers. Nebulized delivery provides an effective alternative for these patients. Currently there are no approved LABA+LAMA combinations available for nebulization delivery.

AERO-007 is a propriety inhalation solution formulation of fixed-dose combination of LABA+LAMA (indacaterol, AERO-001 and glycopyrrolate, AERO-002) under development for delivery using a general purpose nebulizer.

This study consists of two parts. In Part 1 (Phase 1), 8 healthy subjects will be randomized to receive single doses of 4 study treatments in an open-label, crossover design (low and high doses of AERO-001 and AERO-002). In Part 2 (Phase 2a), 16 subjects with clinically stable COPD will be randomized to receive single doses of 3 study treatments in a double-blind, crossover design (low and high doses of AERO-007 and placebo) administered by random sequence.

03

Conditions studied

  • COPD

Keywords

  • LABA
  • LAMA
  • LABA/LAMA
  • Inhalation
  • Nebulization
  • COPD
  • HVs
  • Single-dose
  • Crossover
  • Randomized
  • Placebo-controlled
  • Bronchodilation
  • FEV1
  • Indacaterol
  • Glycopyrrolate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Cohort 1 (Healthy Subjects)

Inclusion Criteria:

  • Male or female aged 18 to 55 years
  • > 80% of predicted normal (using the Global Lung Function Initiative GLI 2012 reference values)
  • > 18 and \< 32 kg/m2
  • Female subjects of must not be pregnant, breast feeding or lactating and use, with their partner, a male condom plus an approved method of highly effective method
  • Female subjects of childbearing potential must have a negative serum or urine pregnancy test at the Screening Visit
  • Male subjects who are sexually active with a partner of childbearing potential must use, with their partner, a male condom plus an approved method of highly effective contraception from the time of
  • Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead and clinical laboratory assessments at the time of screening, as judged by the Investigator
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Any condition or abnormality (including medical history, clinical laboratory, ECG, physical examination, or vital sign abnormalities), current or past, that, in the opinion of the Investigator
  • Lower respiratory tract infection within 6 weeks prior to the Screening Visit
  • History of of any organ system, except for localized skin cancers, within 5 years prior to the Screening Visit
  • Major surgery (requiring general anaesthesia) within 6 weeks prior to the Screening Visit
  • Positive serum surface antigen (HbsAg), virus antibodies (HCV Ab) or (HIV) 1 and/or 2 antibodies
  • Chronic viral infection or immunodeficiency condition
  • History of any drug and/or alcohol abuse in the past 2 years
  • Current or previous use of tobacco, nicotine products or e-cigarettes within 6 months
  • Smoking history of > 5 pack years
  • Regular alcohol consumption in males >21 units per week and females >14 units per week
  • Positive urine drugs of abuse test and/or alcohol breath test
  • Donation of 450 mL of blood within 8 weeks
  • Known to any ingredients in the formulation for AERO-001, AERO-002, and AERO-007
  • Participation in another drug study within 30 days, 5 half-lives or twice the duration of the biological effect

Cohort 2 (Subjects with )

Inclusion Criteria:

  • Male or female aged 40 to 75 years
  • Clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Report, 2024 for at least 12 months
  • Post-bronchodilator spirometry (within 30 minutes following 4 puffs of salbutamol) demonstrating the following:
  • FEV1 > 40 and \< 80% of predicted normal (using the Global Lung Function Initiative GLI 2012 reference values)
  • FEV1/FVC ratio \< 0.70
  • ≥ 150 mL increase from pre-bronchodilator FEV1
  • Ability to change current COPD therapy and discontinue long-acting bronchodilators for the duration of the study and short-acting bronchodilators for 8 hours prior to dosing at each treatment visit
  • Current or former-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, 10 packs/day for 1 year)
  • Ability to perform reproducible spirometry according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines
  • Female subjects of childbearing potential must not be pregnant, breast feeding or lactating and use, with their partner, a male condom plus an approved method of highly effective birth control method
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Female subjects who are pregnant, breast-feeding or lactating
  • Current evidence or recent history of significant comorbidities; including cardiovascular disease (such as myocardial infarction, cardiac failure, uncontrolled hypertension, or life-threatening arrhythmias), uncontrolled diabetes, neurologic, psychiatric, hepatic, renal, immunological, or haematological conditions within the last 6 months
  • Positive serum HbsAg, HCV Ab or HIV 1 and/or 2 antibodies
  • Lower respiratory tract infection within 6 weeks
  • Recent history of hospitalization due to an exacerbation of airway disease or acute worsening of COPD requiring antibiotic or treatment within 6 months
  • Other respiratory disorders: Current diagnosis of predominant asthma, lung cancer, bronchiectasis, interstitial lung disease, tuberculosis, pulmonary hypertension, or other non-specific pulmonary diseases
  • Prior lung volume reduction surgery or history of chest/lung irradiation
  • Daily oxygen therapy for > 12 hours per day
  • Body mass index >35 kg/m2
  • Current or recent history of medical conditions that are for use of an inhaled LAMA (such as urinary retention or bladder neck obstruction type symptoms, prostatic hypertrophy, or narrow-angle glaucoma) within the last 6 months
  • Current or recent history (previous 12 months) of excessive use or abuse of alcohol (males >21 units per week and females >14 units per week)
  • Current evidence or history (within the past 2 years) of abusing legal drugs or use of illegal drugs or substances
  • Donation of 450 mL of blood within 8 weeks
  • Major surgery (requiring general anaesthesia) within 6 weeks
  • History of malignancy of any organ system, except for localized skin cancers, within 5 years
  • Known hypersensitivity to any ingredients in the formulation for AERO-001, AERO-002, and AERO-007
  • Participation in another investigational drug study within 30 days, 5 half-lives or twice the duration of the biological effect, whichever is longer
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    AERO-001 low dose

    Drug: AERO-001

  • Experimental
    AERO-001 high dose

    Drug: AERO-001

  • Experimental
    AERO-002 low dose

    Drug: AERO-002

  • Experimental
    AERO-002 high dose

    Drug: AERO-002

  • Experimental
    AERO-007 low dose

    Drug: AERO-007

  • Experimental
    AERO-007 high dose

    Drug: AERO-007

  • Experimental
    Placebo

    Drug: AERO-007

Interventions

  • DrugAERO-001

    Open-label

    Also known as: Part 1

  • Open-label

    Also known as: Part 1

  • DrugAERO-007

    Double-blind

    Also known as: Part 2

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics - AUC

    AUC0-t (Area under the plasma concentration from time 0 to the last collection time)

    Time frame: Day 1

  2. Pharmacokinetics - Cmax

    Cmax (Maximum plasma concentration)

    Time frame: Day 1

  3. Bronchodilation - FEV1

    Change from baseline in actual FEV1 over 12 hours

    Time frame: Day 1

  4. Bronchodilation - FEV1 AUC

    FEV1 AUC (0-12 hours)

    Time frame: Day 1

  5. Bronchodilation - Peak FEV1

    Peak FEV1 (0-4 hours)

    Time frame: Day 1

Secondary outcomes

  1. Adverse events

    Treatment-emergent AEs

    Time frame: From the first dose to the end of study

07

Study locations

1 site
  • Medicines Evaluation Unit Ltd
    Manchester, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in May 2025, 4 months.

Of 21 phase 1/2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Feb 24, 2025
StartActual
Jan 15, 2025
Primary completionActual
May 20, 2025
CompletionActual
Jun 7, 2025
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06841640
Lead sponsor
AeroRx Therapeutics Inc.
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Jan 15, 2025
Primary completion
May 20, 2025
Completion
Jun 7, 2025
Last update
Aug 1, 2025

Study contacts

Dave Singh, MD
principal investigator · Medicines Evaluation Unit Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AERO-002

Start the discussion